BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM’s First Quantum Computer in Asia-Pacific Goes Online, Set to Open Office in Seoul13.5.2025 11:09:00 CEST | Press release
The expansion builds on IQM’s first quantum computer in the Asia-Pacific region (APAC) installed at Chungbuk National University (CBNU) in South Korea. This marks a remarkable milestone by IQM for delivering and installing the system at CBNU in four months. In fostering growth and innovation in key markets, IQM aims to advance quantum technology in Korea through collaboration with key players. With the appointment of Youngsim Kim, as country manager, the Seoul office will open in June 2025, making it IQM's second office in APAC after Singapore. IQM Quantum Computers, a global leader in superconducting quantum computers, has announced expanding its presence in Asia-Pacific with a new office opening in South Korea in June 2025, following the installation of its first quantum system at Chungbuk National University (CBNU). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513710683/en/ From left to right: Ben Lee and Mikko Välim
Ink Innovation and Riyadh Air Partner to Rethink Experience for Digital-first Travellers13.5.2025 11:06:00 CEST | Press release
Riyadh Air, the digitally native national carrier of Saudi Arabia, is joining forces with Ink Innovation to deliver a flexible and convenient air travel experience. Together, they aim to redefine standards of delivery management in a world influenced by e-commerce, cloud computing, and evolving traveller expectations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513792260/en/ Tony Douglas, CEO of Riyadh Air, said: “Ink is a key partner to Riyadh Air and continues to foster innovation at every step of the journey. As a like-minded tech-innovator, it is an ideal collaborator as we aim to provide an outstanding digital experience for our guests at their first travel touchpoint.” Moving beyond legacy systems Airlines have long struggled with outdated infrastructure—systems built to move passengers from point A to B, but not to delight or adapt. This partnership aims to change that. Riyadh Air and Ink are implementing a full
Green Street Expands Private Market Coverage with European Self-Storage Data and Analytics13.5.2025 10:00:00 CEST | Press release
Firm releases comprehensive macro insights into the European self-storage sector, via its latest Outlook report Green Street, the foremost provider of commercial real estate intelligence and insights, has expanded its private market research coverage to the European self-storage sector. Utilising 5 years of forecasted insights and 10 years of historical data, Green Street’s new Self-Storage Outlook focuses on investment opportunities available in 30 European cities. “Living quarters are becoming more compact and storage space is being cut back in urban developments, necessitating off-premises storage solutions for residential occupiers. Additionally, approximately 40% of the business customer base consists of small-to-medium-sized entities, particularly online retailers in the region,” said Marie Dormeuil, Head of European Market Analytics. “The growth in real spending on storable goods is expected to increase at 2% per annum over the next five years, supporting healthy demand growth.”
Oracle and Infobip Enhance Partnership to Deliver Global Conversational Experiences13.5.2025 10:00:00 CEST | Press release
Global cloud communications platform Infobip today announced that it has enhanced its partnership with Oracle to bring conversational experiences to businesses and brands globally. The new integration enables Infobip and Oracle customers and partners to access Infobip's omnichannel services through Oracle Integration. Customers increasingly expect omnichannel communications, but integrating and managing new channels can be time-consuming, requiring complex development, deployment, and organizational processes. Infobip’s new Omnichannel Messaging Adapter for Oracle Integration addresses this challenge byenabling all types of businesses to work with and manage omnichannel messaging channels involving Oracle and third-party solutions, including WhatsApp and RCS. The solution deploys quickly, reducing time to market. In addition, Infobip has provided a prebuilt use case – or Accelerator – for Oracle’s contact center solution, Oracle B2C Service. This Accelerator is a flexible solution that
Galeria Teams Up With Blue Yonder to Enhance the In-Store and Online Customer Shopping Experience13.5.2025 10:00:00 CEST | Press release
Germany's iconic department store chain deploys Blue Yonder’s AI-driven demand and replenishment capabilities to strengthen its commitment to quality and convenience In today's rapidly evolving retail landscape, consumers increasingly seek personalized shopping experiences tailored to meet their specific demand requirements. For omni-channel retailers, success depends on seamlessly delivering high-quality products and excellent customer service powered by advanced technology that effectively supports a demand-driven, omni-channel strategy. That is why Galeria, Germany´s leading department store chain, has chosen to deploy Blue Yonder’s demand and replenishment capabilities to strengthen its supply chain and enhance operational efficiency. This strategic investment enables the retailer to deliver a highly responsive and seamless shopping experience across both in-store and online channels, reinforcing Galeria's commitment to quality and convenience. Galeria previously relied mainly on m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom